ATRA - Earnings call transcript Q3 2019 | Atara Biotherapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Atara Biotherapeutics Q3 2019 Financial Results Call. At this time, all participants’ lines are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded. [Operator Instructions]

hand over to today, your like Dr. now the to conference speaker I’d President and Investor Atara Craighead, of John Vice Relations Biotherapeutics. Corporate of Communications Please sir. go ahead,

John Craighead

updated Atara’s recent Call. operator. Quarter third plan quarter you, Good as everyone, and our third as press welcome Thank we well strategic results, providing as an Earlier section an morning, company’s issued to well the release discuss press a Media release XXXX presentation operational today’s in On to quarter morning, available Conference This this financial of XXXX. & call, clinical, are the investor as overview we and Investor atarabio.com. at Third progress.

and Pascal joined President Koppikar, Executive and Dr. today’s Chief Chief Officer; Utpal AJ Officer. Medical by I’m Joshi, on Dr. Touchon, Officer; Financial call Chief

prepared We from will your then Pascal for call open with comments begin the questions. and

the our remind forward-looking implied from to by like statements. entirety company would with are uncertainties due to the these company’s results filings. the made associated statements listeners statements. of those are could Actual making business. We management materially These forward-looking risks to differ that will and be or These their and company’s statements today’s stated by and obligation in qualified in statements cautionary statements SEC date today’s as undertakes press release no forward-looking the contained the update company’s

to and Chief President Touchon. call Executive Atara’s Now over I’d the to like Pascal Pascal? turn Officer

Pascal Touchon

us everyone, joining you, and this you, Thank thank for morning. John,

achieving vision results is our every team to strongly an T-cell I depend to and We am to the on meaningful time. toward of patient our in of and any we made need know discussion Before patients recent company. deliver off-the-shelf this immunotherapy day how reinforce the motivated advances begin our us allogeneic I for that proud our delivering want every on we’ve at progress, vision lives

provide and call, milestones. new context strategic progress, operational surrounding upcoming recent clinical today’s and our we’ll During priorities,

have Atara’s on leading as following Objective and T-cell diseases. to of immunotherapy first allogeneic of update transforming life resources extensive First, review assets, would cancer, strategic during the you technologies, moving to the I autoimmune priority, with month objective I patients viral the become off-the-shelf like conducted that my and is organization forward company, CEO. and

this are three the planning on We to resiliently over by strategic executing next accomplish priorities. objective years four

relapsed/refractory and First in with the launch and well tab-cel and develop patients EBV+ indications. Europe U.S. foremost, or tab-cel for for file tabelecleucel as other as PTLD

ATAXXX allogeneic achieve clinical immunotherapy. concept with T-cell EBV Second, proof MS-specific or of

And develop Third, immunotherapy of CDXX expertise programs development. In for fourth, advance of mesothelin ATAXXXX the leverage allogeneic of autologous CAR in partners concept external ATAXXXX therapy continue to or with clinical parallel, and allogeneic ATAXXXX. proof capabilities malignancies. and autologous to we’ll T B-cell

program of with multicenter from access ASH only to the highlight eligible EBV+ Phase likely cell XX long-term outcomes organ treated abstract to to ask would PTLD long-term we at Starting in for outcome of with data, expanded share acceptance tab-cel, We had an I subgroup a III XXXX. study. presentation with relapsed/refractory and stem of very exciting been are ongoing tab-cel. transplantations our XX pleased a following like would

response These XX% two-year results HCT and EBV+ of Estimated with with overall patients. survival patients XX% XX% demonstrates of in XX% previous clinical survival strategy development relapsed/refractory overall large tab-cel durable SOT studies was showing for these rates in HCT such profile, overall response two well-tolerated reinforce follow-up, patients duration amount data with high longer and for and years, PTLD. rate our that SOT. to and and a generally lasts of regulatory safety are With consistent well-tolerated for

transformative immunotherapy physician interest deadly patient, off-the-shelf is in often that confirm with These compelling new cancer. potentially this also for tab-cel the value ultra-rare T-cell allogeneic data

BLA tab-cel tab-cel, enrollment the in for program to for Canada open Australia, the have the initiate transplant coming development with available centers PTLD continue second sites clinical half additional plan over to the U.S. EBV+ pivotal our and and now XXXX. patients to in XX of remain sites at track We submissions U.S. Turning for we in months. and on to

a We discussions also the year. EU we several authorization PTLD. determine will trial timing plan application application and of of these discussions outcome sites EBV+ by patients to EMA conditional the tab-cel year, there or marketing engage the for file to end clinical open study countries European in CTA with this of and the Meanwhile, in the next with

the ultra-rare pivotal submission BLA of our Our rapidly takes an due PTLD disease. constraints to nature in inherent progressing study and into guidance as recruitment account the

constraints number Our these at clinical open constraints. be Phase patient’s the high have should order to for immunotherapy. advanced, could be a transplant T-cell Also U.S. of to there within XX% in days III transformative we study have of limited And trials. three a competing, are need. believe development impact patients the are we individual less will only on upgraded these July, about such of with any center appropriate business delivered an we Since the PTLD. And value are tab-cel potentially although way case site to addressing importantly, the tab-cel also Indeed,

by indication market tab-cel if on tab-cel proven patients we per The the safety. XXX sites and year. several approved PTSD, is U.S. it where patients serve potential treatment will and first physicians And likely for efficacy supported becomes be based

together business we in EBV+ these sale relapsed/refractory Taken tab-cel to the with that the a Atara believe opportunity geographies. commercialize there case strong for PTLD in profitable potential and Europe, is in

also We’re studies tab-cel. additional in indication for advancing potential

tab-cel platinum-resistant I/II recurrent clinical continue NPC. anti-PD-X of our EBV-associated or combination in therapy in with with patients We to enroll in patients Phase study

EBV+ these as in the continue enrollment the to multi-cohort opportunity cancer of in in potential of half Phase tab-cel. XXXX expect to study disease second start the proposition a also value product. ultra-rare targeting the II value for show an We expanding tab-cel pipeline studies other Overall,

for living Based on with Now progressive initiate the MS. we study. of a in cohort patients cohort this ECTRIMS ATAXXX. least data experiencing the in corporate of Phase data Ib Phase Ib we on priority, study than cohort patients improvement improving turning are six more to well-tolerated the initiate site. on dose. to criteria our data, reviewed and the with that share to September the reported taken Recently XX% X was X encouraging of X achieving based second pleased selected this safety portion dose assessment at patient to at clinical we decision months follow-up have We continued our profile from one clinical based coming pre-determined defined multi-scale The since

MS limited in treatment development we from Recognizing decline whom these is data options who experts, external believe expected. acceleration for merit results patients continuous are have and progressive and input the incorporating these of early ATAXXX

data cohort In an fourth is mature congress X and final in be addition, client detail XXXX. I data will XXXX. appropriate from enrolment April in in in We Phase cohort cohort to at Six the months present plan all complete. escalation then dose

Following with move and in MS. Phase our with complexity such product II encouraging for as reduced study We’ll we strategic decision for efficient to This cost. resources allow ATAXXX associated the autologous ATAXXX. focus operating and our results options will study us execution decided or on evaluate on continue not ATAXXX ATAXXX focus manufacturing autologous well as strategic to line ensure therapy, allogeneic to forward have T-cell in to

an PD-X planned to potential for ATAXXXX work priority ATAXXXX. our XXXX. and these Our is mesothelin-associated autologous due negative Both while dominant CAR platform. first for we T to programs ATAXXXX advance which tumors ATAXXXX, strategic T ATAXXXX around the co-stimulatory EBV great is CAR a of enter leveraging of IND development our will solid is programs, have the clinic an a CAR in first, XXX of T, the mesothelin-targeted allogeneic novel T and receptor. cell domain incorporation mesothelin

EBV T. asset and ATAXXXX is will IND strategic currently CDXX allogeneic to evolve T platform. CAR demonstrate cell CAR with clinical first the or This later study in Finally, internal for Atara’s proof-of-concept goal to priority is preclinical our

that EBV intend vivo we responses. and of to persist high Ts response more traffic safe, to CAR rate show obtain durability and are expand efficiency in Here sites allogeneic to

manufacturing clinical Commercial strategy. ATOM to are qualification our updates. and activities and facility Turning few complete. support are commissioning operational progressing to at commercial production our with a operations Facility development aligned and qualification well activities

a Additionally, Counsel. process adapting Research This to effort I Global of of efficiency, Head maximizing includes expected priority. a and strategic CEO, a active searches operational of new will and new at team a be Head now a by in Operations, General leadership new my a am a Development, and rather for Commercial

results. Before opening I quarter from to reflecting the quarter a the with the financing. would $XXX.X secondary questions, ended comment call We our million, to like cash follow-on of on financial balance XXXX proceeds recent – third for

fund continue to and growing operations expect cash have in to to XXXX. We

questions. your to over we to and the so I take Operator? ahead would back now can turn like the go operator, call

Operator

our [Operator from Instructions] Anupam comes from And JPMorgan. question Rama first

is line Your open. now

Anupam Rama

congrats the need past, taking In to on PPMS and the emerging all to patients the long understand we’ve for Thanks term kind guys. of What ATAXXX. XX-month, follow clinical are Great, the progress. not the in talked in at are truly that’s here questions about XX-month six-month time the forward X you giving points you to the confidence seeing really cohort of point dose available? given profile move time the

Pascal Touchon

for AJ your question. Anupam, in will there. will start maybe and I Thank you, chime

points moving built evaluation So you the Phase Ia for one-year clinical study are as Phase to there. is of for the clearly, of forward a predetermined These the time know, different as study, we patients criteria Ib. assessment with

course XX% that results reached months six with and results but when one add this believe situation data only improvement dose cohort want accepted decision AJ, for we particular this at profile, also which for more on you will this months. in safety cohort different the have X that? course, at particularly to of clinical move than we comment least well while we data of we Ia shows yet don’t Ib, to patient six have So these for these have That pursuing our have have we not coming site. do that hands, having on mature we X merit more And in the this we the of data. we acceleration

AJ Joshi

up it early endpoints. set we style frame to take and the does just criteria really a some to your find other Anupam, recalling to the Sure. longer have some because EDSS that those point, signals those of we try time – used, specifically of criteria

this specifically for So early approach again, looked signals.

because used having points. there was scales scales on seven high, bar Now when at we were separate different talk clinical on improvement we two the XX% the required consecutive and relatively based an improvement, about approach, time we

time means six our months, So months at and those measured we that are points. three

You’d at those scales have points time to on the patient. have improvement for two each of

than more discussed what, want we a open label an also site. we happening these when that relatively said, with one that make it’s study, high the thought And know [indiscernible], for hit. bar improvements us sure are yes, they at we to that And then was you to

target was So these plus at XX% different XX% sites. two it improvers hit – the was that we

intent So this the detection. bar us was early it detection. confidence high the to that’s a early kind high of we a have because bar did and was what using that set gives And signal

Pascal Touchon

be in XXXX. And Congress additional Yes. say, at will as be XXXX details shown we there appropriate to

Anupam Rama

and Thanks the congrats progress. Great. you. so much on Thank all

Pascal Touchon

Thank you.

Operator

Thank our John comes question you. Canaccord. next Instructions] from from [Operator And Newman

Your line open. now is

Christopher Liu

This taking thanks question. Chris the John. my Hi, on is for phone for

ask we to enrollment. additional wanted you’ve in Canada U.S. color clinical get just if And I more on opening the and also any the sites could mentioned So

like Just are guys about? timeline how and you thinking look wondering sites what would that many

Pascal Touchon

Chris. Thank you question, for the

in In second aligned with guidance for progressing be to half is terms enrollment the XXXX. submission the as initiating enrollment, our of planned BLA of

part on, study the in recruiting a the patients of transplant earlier sites we expand because XX% is about in mentioned are we challenge of today As need this sites U.S. to number the only of more in

we open for continuously So this done In of the to necessary the time and sites. running. the number sites This U.S., is be are increasing takes two way. these

once that’s And in the in approval into start Canadian open July, now of CTA to a had the moving CTA year redo obtained through next have to in opened European stage the the site then Europe and will next in in are the file end usual why we opening really the Australia. five Canada. year, And the by We in where of of countries. process the to we’ve going be we’re gone authority countries these from Canada, site specific to past able already several be then

Christopher Liu

Got Thank very much. it. you

Pascal Touchon

You’re welcome.

Operator

from Securities. from our next comes you. Syed And Salim Thank Mizuho question

line Your now open. is

Salim Syed

Congrats Hey, guys. questions. my on taking Thanks the much very progress. for

for couple a me. Just

sell just move on actual either specifically, not So or little X without it’s you wait not also address X mean about then were cohort on you and making you give Or to think can more there when say you’re X, a it of no developing cohort color? here it cohort that or are part at a the this product? why can you and longer planning of options, And to Do market? data? part thinking was reason you decision you waiting to you’re us Does holding strategic forward time a evaluating the different X it? you’re decided – ATAXXX. for theoretically the a for cohort to commercial When that

Pascal Touchon

Thanks, first with I the AJ, the can Salim, you start take for your good Maybe will second questions. one. one,

AJ Joshi

Sure.

So good it’s a Salim. question,

know And thought cohort was think, high concept, we pre decision such as bar. for unmet that with decline you kind of remember, good. three should extent, for expect be And we think They here we a clinical didn’t – we’d cohort in was have despite relatively what, of improvement. a because the those our I I and hit criteria top And when we it high those up. X because leaders the To the decline a no-go, these use patients mentioned a nice pretty dose things have this our baseline And pick looks measures we’d predetermined X. earlier, actually, had that, even zone. that. should need patients the everywhere, it some is population go, hit there’s that middle right. we some And

dose. So a cohort made move it to forward with sense X

timeframe. But data in will some because the we’ve optionality April as X also the for the we dose six-month left data get the cohort in, mature ourselves

if at to evaluated get in, dose look that a to those up well. we’re set adapt we protocol data as actually to a X, we to we’ve signal take cohort need suggests seeing a already be allow our that for As plan

ourselves We in for and and So here. for sense better feel need relieve dose to go have both, at high no a like holding us, have we options we good may medical given a the but now. unmet back dose

Pascal Touchon

we wouldn’t I mean, these two your for ATAXXX We stage program these offsets, I in the question, we And as where say there Xb. ATAXXX bring Xa we’re side by at believe had and therapy, explained there. that to bit say chronic allogeneic because first clearly But even were advanced let’s for results, in this T-cell start therapy the having were same II significant disease, these Salim, second they focus we ATAXXX, a allogeneic of ATAXXX past. to clearly encouraging for the of a more development. a ever with followed a T-cell disease ready about advantages was on the autologous time going offers being compared of Phase with

we concept way. don’t right advantages. a we autologous clear our what also of focus resources see Ib want on Phase in the bring rapidly of delivering proof now And could But from terms placebo-controlled randomized some to double-blind in

creation to options. on now. want There and results. this for really more can expert, focus support So key resiliently the And we the development the once we and for the considering and truly will accelerate because we and achievement our the criteria are for patient for company. ideas of that we we the keep right these review proper value of better is the company the specific predetermined of with patients element based excellent and have execute portfolio Ib Phase on are the But XXX in other to

Salim Syed

so Thanks Great. much guys.

Pascal Touchon

Is that fine?

Salim Syed

much, perfect. Yes, much, Thanks Thanks that’s so so Pascal. guys.

Operator

comes Company. from Cowen our And question Nadeau next Thank you. from and Phil

Your now open. line is

Phil Nadeau

my tab-cel. Good earlier to Thanks guess a I morning. an A few taking for questions. first follow-up on question.

two guess open Trials U.S. think U.S. it of been have is, XX% is for in centers? question now. I years. you’re that XX% close I just the centers mentioned to of why You

the board been sites has on getting in U.S.? what up hold the in more So

Pascal Touchon

want I think, to answer AJ, do that? you

AJ Joshi

Yes.

focused are think, wouldn’t the and we hired patients. decently secondary be you ones centers Then I like it there at, to the in. Where those most at in of medical we in geographically feel patients are best to the where going team going centers, I a when have – call are top seeing that the fairly suited on we’re a where of hold to up. the for those – that found centers necessarily that the kind a them to centers science or those we are actually if seeing be sized have structure those out so not reach We have to we to we additional a we’re that refer – liaison being now. kind XX

there’s and to transplant try that XXX really at an XXX an So, intent to in transplant an never going zone we’re that a It’s continue. There’s be now. Doesn’t mean, centers in – it’s to optimize to to – centers. country. really not we’re over not intent centers the there’s

We patients but found really goal centers to And the from get centers would Canada other it. they’re key centers, add XXX then through and the be be the in at never are continuing course, Europe be try the geographic we The whatever, to top of expansion of there. to next to part will centers. refer when to

Pascal Touchon

And I potential MSL for starting are we enrollment. awareness patients we to with identify use July, eyed would that to transplant add evaluate claims artificial continue suitable additional since to have data to increase intelligence I And also technology to and also HCP feel centers. at interaction

our So efforts upgraded there. we have

efforts we to guidance. with able So number it’s have record accelerated since centers, to all of not our only line the in done it’s the July be and

Phil Nadeau

on is filing guidance. the second U.S. Then

do the sensor will in guidance completed? You be be of modules mentioned when second first? some the XXXX. filed be for a And will a you initiated filing or filing half What will have

Pascal Touchon

analysis will be filing in as – time, has based initiation will on this last said filing we based protocol. pre-specified interim an been of that this So our be

And at some mentioning FDA the think time of that we’re up the last there. six of a why is months we And is BLA very FDA following that requests I with in specific stage, response. the follow the these there this word follow-up for terms of that’s from filing of patients. initiation So you shared asking

is the two first response being after So months identified infusion. at usually

follow-up months months two So enrolled eight the six of from patient plus about months, last being there.

aspect So account. that’s an take to into important

Our hand BLA a initiate of be population. the we half filing for total analysis the been to in the will on that interim this one of guidance clear XXXX able on part the based second has

the track CMC course, really absolutely And patients is recruitment pre-determined is On there. the limiting all is enrollment analysis of the schedule. There for on of pre-specified the It’s number and other on no that aspect interim issue the hand, of and really other needed this filing. for the on factor achieving the for of and It’s patient timing. there.

Phil Nadeau

will given or when date the you initiation data first? – upon follow-up be a by have PDUFA do you the get to in of it So the six-month Will be filing be decide FDA? that to

Pascal Touchon

process as FDA I will move to possible review so what the see a we is patients. say discussions the that would expected, very way our our been them like to for is so and forward discuss best This data a and in far truly because pre-BLA to these with with meeting FDA they has go how far. constructive the

to indeed to very results transformative level So the will we believe bring find we the that the if we optimistic best therapy be. possible at there could they are way are U.S. patient this

Phil Nadeau

And for one me. question last

when issues on discuss for a what the you to EU, continue the clarity filing? necessary guidance any that European the And update you can be us and Just the a with will see for from an EMA? on give you regulators

Pascal Touchon

Yes.

fully we that also in as system with system I a constructive not on in transformative some a levels, the EU, designated We with We EMA. really PRIME is this a to a is know, FDA PRIME give the which we And say, repertoire change the them. and going where the timing. dialogue supported with EMA. sure challenged of PRIME importance with EMA produce terms by are that is you that the interactive quality is system And protocol by interaction there dialogue are dialogue SOT specifically this in for therapies would joining discussing guidance following type the we to that’s one. that the make is into on of agree want the of two the have alignment to for because

we make for inform will and conditional view when we on you believe we So, have when progress approval. there clear we Europe file can when a in we

Phil Nadeau

Perfect. Thanks my for taking questions.

Operator

next comes question Tony Thank Capital. from you. from And Butler Roth our

open. is Your now line

Tony Butler

that question Thank made study. the the an EDSS future you – to you – to maybe provide of gave ahead Ib looking And Pascal, if about may. criteria I’m you’re reference very you you XXX question much. to study, do you of about in early is their my patient theoretical about as stated, And when portion actually that with scores not EDSS those actually see think about more progresses more the earlier could on question that a signals AJ, to you second hire criteria the may therapy? about do do So if confidence in second, a But ask the might how want duration question then you to the patient tell think think you forward that What in those signal? that initial beyond early move person? have what you R&D? you us Phase that known. happens improve have And is signals with on and question is, you clearly something at you the – when is the view? I that of some that

AJ Joshi

improvement clinical the programs few and what if companies, There’s is you bit always have at this products about There is very think really people we’re future really a when perspective is going few about that ever thought not be now. maybe few clinical might improvement, to looked very overall MS. talking very about so Certainly, you into – that. an when – getting give to you you little imagine because just Sure, difficult.

some it kinds measures. So have ones at of you variety that looked would disability improvements a that yes, have the anticipated see of over in time,

at EDSS, they’ve disability looked a haven’t of just looked variety when looked, measures. So they they at

composites. as sometimes separately, Sometimes

a you for for So in fashion, would okay, like we something our think you you look about, as at – if product look would if similar improvement, are you looking that.

it. the I So Obviously, maybe going mature going to that’s over continue answer data we’re best XX can have to to that��s time. months way

XXXX. be that XX months data So of style presenting we’ll in

So have a view we’ll it. cleaner on

we do I So of that’s best in expectation. can the But question. future. guessing terms I won’t that the into be answer hope the just

Pascal Touchon

I appreciate it...

AJ Joshi

One other actually, sorry, would Pascal that say, like the point we – an Phase extension. are of is Ia to the continuing we open for label I study, sorry, portion are

So we will be this XX patients. Ia having annual dosing. In additional that, we of information long-term will Phase group also get on some entire

Pascal Touchon

That’s on. exactly point the to I add wanted

On we’ll continue of the there. continue the and response physician to Ia, we’ll – when about and inform us experts durability

turning to your So question second now there.

was the possible clinician that being knowledgeable By we be what ideally an a cell have think – a that for ideal we a in ideally have looking I as profile. as close well. have we profile. mind that’s oncology, from to transplanter Ph. are is I And I therapy, and D. the about in in to ideal try is mind clear MD mean, as scientist physician, clearly

of to finish in also developed We product, FDA approval approval. in post particularly EMA oncology, have terms the and getting

to who excellent in the product forwards operational and a true execution and and company there bringing leader biotech in someone large been projects finish company line. worked And both bringing in has forward has and execution

of collaboration, insist in is scientific that we sense that’s strong now of lot And what excitement and the for a have amazing the Clinical – And cetera. of these that I’ve of It’s Joshi, our is So individuals leaders, team us the the a what experienced type technologies, basis am are with candidates. also today. benefiting we is Head that that’s our I these platform, from but of AJ call with been the way I benefiting to Development, would at really we who meet starting in bench the various of have for CMO myself like with disposal have our we et there something developed quality upon mind. will very the that technology we to potential

Research, Preclinical We have of our our Affairs, and of Renu Blake Vaish Head Regulatory Translational and Aftab. Head

batch, So the capable knowledgeable are very that people and there strong leaders, development. supporting very very experienced value

We company, MSK pipeline to technologies, our in on Marco experts there, role from Michel not from and the from Khanna all also with different from direct advisory Prasad the but support and an from Davila continuing CSO, in is programs Adusumilli, Haqq, field: our Moffitt, Chris Richard benefit who with key Rajiv Sadelain Former academy O’Reilly QIMR. only

we are who So to active our expert I in your strongly field, are from as we where supported to especially Europe of really some are MS add from technology. experts related by discussion and working in that and advisors, key we these science also part our And but with the more key question. only well. hope not Australia, more and U.S. from I answered taking

Tony Butler

sir. Yes,

did. You Thank you, Pascal.

Operator

from Goldman Thank you. And Salveen Sachs. our next from Richter question comes

now Your open. line is

Salveen Richter

me. I strategic a for Two guess, question is here. my taking Pascal, questions. one from Thanks morning. Good

then question sites transplant submission? CAR gives you following versus the in the half the after CAR-T to that – CDXX other given given U.S. T XXXX As you on just XX% And a you hit this EBV BLA program the targets said, there why apart of Phil question just maybe what going confidence only crowded creating pipeline, would some just look allogeneic space you from go second what into that just open mesothelin? to the second a your as your for you nature up can have

Pascal Touchon

Thank question. you for your

assets to you the a CAR look deck now. to And new different So for different I with T first one recommend to that’s slide the Slide right let’s is that investors trying There maybe we our in have one. the X-X. that have see XX, we start explain how

clinical or And, allogeneic as stage the ATAXXXX. accelerate to you mesothelin we also developing need CAR-T actively of a our the at clearly have mesothelin We autologous T. development ATAXXXX a preclinical CAR know, are stage version of

clinical of Now allogeneic stage the some which CDXX pursuing currently get we appear the can get will where with what other that can that reason also really a to some space, we the we with clinical there. allogeneic in and result approved ATAXXXX CAR-T development is EBV to we platform based faster of compare are there product are because type there starts to autologous, go

to our is We a these that could strongly lead to T needed persistence based and that as level trafficking only of well believe patients, not the CAR allogeneic treat but to EBV aspect has platform. expansion, and of T-cell of believe there. one think tolerated the very way of I response durable of significant one been Persistence and the have is a that key allogeneic of And of level safe the challenge type many there. response I

you the more as persisting long there. type of remission and that different cells system know, our shows are of that data, patients, enough to for have the in other cell that few We and experience

to would the definite but platform and a only not exist concept, we that with same the T right We be that than like we now. proof we suitable allogeneic for T, show platform of have CAR CAR and allogeneic CDXX for better will other platform any believe construct have the a

be how ability malignancies, could in hope and other some the as one. So results there. rapid think to approaches allogeneic we of will way CAR autologous from believe, do I to we us effort answered hopefully, so concept of on the do our compare platform I again, we able proof other to of type all in and that that’s data we will really superior allogeneic question that particular to so be other early program, to why T, And help of where from to to terms the disease, of data your B-cell in have other existing and that get. a support show it’s type in

we the of Canada, we’ve of on you patients but in of from Europe, study. what are said, about U.S., in number will in as site, of imagine the role new site on a play terms And then in XX% pivotal number can the later recruiting significant enrolling increased said, of the we site, as these that all and in

that from been course, We benefiting has are, of done. the here work

is guidance the XXXX right giving what rate now. half based second seeing month’s the we’re on on So about line we’re with of whole reasonable in the the

of want number right able guidance, our our shareholders. we site important. something that’s to objective. to we need now. what to and for It’s as is execute going of which to estimate in we’re expected be to line work in deliver help the would our Any to patients increase to expected in as be like to able So us continue is the is be with for what We reasonable and seeing a terms do

Salveen Richter

Thank you.

Operator

Thank comes our question next you. Ben And Stifel. Burnett from from

Your now line is open.

Ben Burnett

on program. on stem group Thanks progress. cell have the I the expanded specifically so reported Congrats about question transplant I that yesterday. much. the Great. access guess you tab-cel a

severity lower bit was ORR any was which previous if reported than analysis more the is a But of think differences Obviously, between I terms I are original, notable in were disease of in that patients. and new analysis the the it a just yesterday new this XX%. included think, versus wondering EAP patients was there enrolled XX%, or characteristics? –the the baseline into six I there’s five

Pascal Touchon

for Ben, you, want question. one? take Thank to you AJ, your that

AJ Joshi

Yes, I significant wouldn’t is a say difference. there that

have did HCT to abstract, them group. the risk. patients an kind of to SOT to risk intermediate of high relative the you higher general A see proportion were high in the As in intermediate

a bit patients, it’s a honestly, sicker patients. of generally were but number small they So

So from I I read, least – wouldn’t that. over our read at wouldn’t

think across XX% study the we’ve – of pretty key populations data ORR for are been a presented. all everything on. bit I reported has generally different these us we’ve point We’ve XX had to consistent that little almost with the eight over

So for me, fairly consistent deal. still it’s a

Pascal Touchon

the encouraging by XX% is of on I And have the XX% fact the important. full survival years. of that The to think very – population also overall two terms on – there responding, ability is we extremely in a there something that way, the

Ben Burnett

That’s helpful. Great.

maybe the Okay. tall, articulate if ask more on bit little you follow a to could up maybe as a question. Salveen’s then I just Could just mesothelin one on strategy XXXX more, assets? I And a The just guess. regards with the

guess So shift some there point to this a on away at I focus from is plan asset XXXX?

Pascal Touchon

question. Thank you for your

think clinic from We we this with domain to Here to integration is due both to generation potentially going XXX XXXX. physiologic that believe it’s to I of immunosuppressive to for type to the first activation the assets. going there. said, more as an from preclinical of way target CAR persistence, environment the also there the a of the on initial of is we T. is PD-X believe the We of have data DNR we And these data, the addressing T-cell CAR the intrinsic encountering the address its disease are, which co-stimulatory impact ability our and on T superiority to offer in go the with priority want

that. year. clinic this confident next is very on T autologous the And we’re to CAR to pursue idea going the So

clarifying first And of proof So, moving we accelerate pivotal human, we dose if start will study, the to concept. with into in and so. we could a then do hopefully

So aim moving but moving approved there. the not is only that to accelerate be our could through really that’s to a clinic, product ideally

concept of time as an is And terms the Now version well, efficacy T we safety in delivery proof allogeneic some as significant achieve and as the that is able beyond reasons. patient clearly, of is of course, that accelerating adding because cost pursuing But days offer and we move as to allogeneic type clinical ultimately, terms believe what through of some that can on be that ideally inventory, in a more fast and advantages to same in space. us are good goods of clinic for will in of to within priority of to three and a possible that we for for the terms CAR study. people particular ATAXXXX to significant

Ben Burnett

helpful. That’s Got it.

the Okay, thanks and congrats again on progress.

Pascal Touchon

you. Thank

Operator

you. from comes our from question Raycroft Maury Jefferies. next Thank And

Your now open. line is

Maury Raycroft

taking thanks Hi, my everyone, good for questions. morning and

just tab-cel. had a program patient I use on So, the for question and access early single

treated patients? update you patients patients you in now? tab-cel you an how point? update these Or from update at on if programs? provide a do those provide providing those data on you many plan And wondering And an with acquiring some the general on then on patients are could specific you Just could

AJ Joshi

Sure.

probably is though kind total couple for there. a of number you access across this in will not tell groups, of numbers all this, program. to patients exact XXX I So expanded of of What going the be giving example, we’re terms about different things

we you about other so that seeing. talking congress, be So are we’re the going do to plan some we a at data patients? on populations other the of some of future on providing talked about Yes,

it’s we’ve think figure that study XXX. that’s important data to our that do how gained we study. us to we’ve to XXX are have information the I necessary That’s PTLD for talked the the the utilized that plan we we’ve of because thing got multi-cohort is requirements off the to XXX want that out that data patients study, that understand in those actually got given not the XXX about

the will at So presenting gotten that point. be is we’ve data that we useful, and some future

Maury Raycroft

my Thanks questions. Great. for taking

Operator

concludes today. that question-and-answer And Pascal remarks. the Touchon turn I’d for to you. for back Thank session conference to closing like our

Pascal Touchon

It’s in everyone call the to you. to you look pleasure very you, day. with today. We Thank very strong. hope great And talking see a Have many on a ASH. year at forward finishing been nice Orlando of Bye. the

Operator

you Ladies conference and this participating disconnect. concludes you today’s gentlemen, call. may for now Thank and

Atara Biotherapeutics (ATRA) 8 Nov 192019 Q3 Earnings call transcript